Detail
| LncRNA Name | Lnc-THOR |
| Synonyms | NA |
| Region | NA Sequence |
| Ensembl | NA |
| RefSeq | NA |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✔ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | renal cell carcinoma |
| ICD-0-3 | C64.9 |
| Methods | qPCR, Western blot etc. |
| Sample | renal cell carcinoma tissues, cell lines (HK-2, 786-O, A498 and ACH) |
| Expression Pattern | up-regulated |
| Function Description | We show that THOR is expressed in human renal cell carcinoma (RCC) tissues and established/primary human RCC cells. It was not detected in normal renal tissues nor in HK-2 and primary human renal epithelial cells. THOR silencing (by targeted siRNAs) or CRISPR/Cas9 knockout inhibited RCC cell growth, viability and proliferation in vitro. Reversely, forced over-expression of THOR promoted RCC cell survival and proliferation. IGF2BP1-regulated genes, including IGF2, GLI1 and Myc, were downregulated by THOR silencing or knockout, but they were upregulated after THOR over-expression. |
| Pubmed ID | 29752937 |
| Year | 2018 |
| Title | LncRNA THOR promotes human renal cell carcinoma cell growth. |
| External Links |
| Links for Lnc-THOR | GenBank HGNC lncrnadb Noncode |
| Links for renal cell carcinoma | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.